Bioresorbable Coronary Stents Market Size, Share & Trends Analysis Report By Brand Outlook (Absorb BVS, Absorb 2nd Generation, Magmaris, Magnitude, MeRes-100, DESolve), By Region, And Segment Forecasts, 2018 - 2025

Industry Insights

The global bioresorbable Coronary stents market size was estimated at USD 69 million in 2016, which is anticipated to grow at a CAGR of 15% during the forecast period. Availability of post-approval, real-world evidence data for Magmaris, Magnitude and second generation Absorb is expected to be the turning point for the current lagging pace of this market.

Placement of these bioresorbable devices enable individuals to live with a normal functioning artery as well as the option to undergo an angioplasty in their later years. While still in development stage, the pediatric patient cohort with genetic coronary conditions are a viable target for these fully dissolvable stents that allow restoration of normal vasomotor function as well as normal vessel growth.

Another key driver for this market is the gaining count of elective Percutaneous Coronary Intervention (PCI) procedures. This number is on the rise, particularly in the Asia Pacific region. Cardiovascular diseases, a key driving factor for atherosclerosis, is driving the worldwide stroke occurrence and coronary artery disease rate. Risk factors associated with unhealthy lifestyles that are highly prevalent in urbanized regions underlie the stroke incidence rate; thus giving rise to a high demand for interventional coronary procedures among young adults. Lack of appropriate use criteria guidelines to check procedure volumes and enactment of National Pharmaceutical Pricing Authority’s price capping policy in India is increasing affordability and penetration of these devices.

Brand Outlook

The market in 2016 was marked with high sales of Absorb BVS, recording 97% in market revenue share, which was subsequently recalled in the second half of 2017 due to unfavorable post-approval trial results. Its withdrawal has sparked concerns regarding the safety and efficacy of these fully dissolvable devices, prompting a greater demand for reliable post-approval data from national regulatory bodies. With more promising patient registry data, other lesser-known stents such as MeRes-100 and DESolve are emerging to the fore.

Anticipated entrants, currently in the pipeline or recently launched, have distinguishing attributes that set hope of revival opportunities for this bioresorbable coronary stents market. Amaranth recently developed three devices, Fortitude, Aptitude and the last with the thinnest strut, Magnitude which is expected to prove favorable in clinical follow-up studies. The first of its kind, metallic bioresorbable device, Magmaris with an underlying metallic body exerts better radial force in comparison to precedents in this market. Abbott, despite its recent setback, is focusing on developing another bioresorbable coronary stent (Absorb 2nd G) with alterations to the previous design.

Over the forecast period, these second-generation bioresorbable coronary stents with improved attributes will gain ground and boost the market pace.

Regional Insights

Europe dominated the global market in 2016 with Germany identified as the spearheading country. Availability of CE-approved stents and absence of auditing to check PCI procedure counts supported this region’s emergence with USD 39 million in revenue.

APAC is expected to witness the fastest growth with a CAGR of 23%. Apart from increasing coronary stenting procedure volumes that stem from the high CVD-afflicted patient count, this region witnesses quick uptake of CE and FDA-approved devices, which in turn is engendering the high sales revenue of bioresorbable coronary stents in this regional segment.

The U.S. trails behind with low prominence in this market. The downfall of Abbott’s Absorb BVS coupled with lack of other bioresorbable stents seeking FDA clearance to capitalize on the opportunity has resulted in low immediate prospects for bioresorbable coronary stents in this region. On the upside, the clinical pipeline of second generation bioresorbable stents with better device attributes and design features is expected to boost sales across the worldwide market, encompassing primarily Europe, India, and North America.

Bioresorbable Coronary Stents Market Share Insights

The bioresorbable stents market comprises mostly new stent players, including BIOTRONIK, Meril Lifesciences Pvt. Ltd., Elixir Medical Corporation, REVA Medical, Arterial Remodeling Technologies, Amaranth Medical, Microport Scientific Corporation, and Arterius, competing against established drug-eluting coronary stent players.

Key strategic efforts among the manufacturers center on the development of new bioresorbable coronary stents with better absorption times, strut thickness, and radial force. Pure-play companies, such as Amaranth Medical has generated three versions of bioresorbable stents for coronary conditions, each with progressively better device specifications. The company’s latest one, Magnitude, is expected to boost this market with higher sales following its commercial availability.

Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the latest trends and opportunities in each of the sub-segments from 2016 to 2025. For the purpose of this study, Grand View Research has segmented the bioresorbable coronary stents market on the basis of brands and region:

• Brand Outlook (Revenue, USD Million; 2016 - 2025)

  • Absorb BVS

  • Absorb 2^nd Generation

  • Magmaris

  • Magnitude

  • MeRes-100

  • DESolve

• Regional Outlook (Revenue, USD Million; 2016 - 2025)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • India